Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Is Sesamol Effective in Corneal Neovascularization?

Kaya, Hüseyin, MD; Pekel, Gökhan, MD; Yörükoğlu, Aygün, MD; Hiraali, Mehmet Can, MD; Şahin, Barbaros, MD

doi: 10.1097/ICL.0000000000000512
Article
Buy

Objectives: To evaluate the effects of topically and subconjunctivally administered sesamol on experimentally induced corneal neovascularization in rats.

Methods: Fifty-six right eyes of 56 Wistar Albino rats were chemically cauterized to induce corneal neovascularization in this experimental and comparative study. The subjects were divided into eight groups: topical sesamol (group 1), subconjunctival sesamol (group 2), topical bevacizumab (group 3), subconjunctival bevacizumab (group 4), topical bevacizumab+ sesamol (group 5), subconjunctival bevacizumab+ sesamol (group 6), topical Tween 80 (group 7), and control (group 8). The amount of subconjunctivally injected sesamol and bevacizumab was 1.25 mg each. Topical groups were administered 10 mg/mL drops twice daily. The control group was left untreated. To evaluate the degree of corneal neovascularization, digital photographs and corneal sections stained with hematoxylin–eosin and CD31 were used.

Results: When photographs of neovascularization areas were examined, all treatment groups showed statistically significant differences when compared with the control group (P<0.001). Topical sesamol was found to be more effective when compared with subconjunctival sesamol (P=0.003). Topical sesamol+ bevacizumab was found to be more effective when compared with topical bevacizumab (P=0.018). The numbers of new corneal vessels were as follows: 12.28±6.29 in group 1, 36.85±12.8 in group 2, 18.85±7.71 in group 3, 16.85±8.70 in group 4, 19.57±8.56 in group 5, 22.57±7.43 in group 6, 45.00±11.29 in group 7, and 51.16±5.91 in group 8 (P<0.001).

Conclusions: The outcomes of this study suggest antiangiogenic effects of sesamol. The use of topical sesamol monotherapy or sesamol combined with bevacizumab may be options for the prevention of corneal neovascularization.

Ophthalmology Department (H.K., G.P.), Pamukkale University, Denizli, Turkey; Pathology Department (A.Y.), Denizli Servergazi State Hospital, Denizli, Turkey; Kilis State Hospital (M.C.H.), Eye Clinic, Kilis, Turkey; and Experimental Animal Research Lab (B.S.), Faculty of Medicine, Pamukkale University, Denizli, Turkey.

Address correspondence to Hüseyin Kaya, MD, Ophthalmology Department, Pamukkale University, Denizli, Turkey, Postal code 20070; e-mail: hsynkaya@gmail.com

The authors have no funding or conflicts of interest to disclose.

Supported by the Pamukkale University Scientific Research Projects Committee (Project no: 1902).

Accepted March 11, 2018

© 2018 Contact Lens Association of Ophthalmologists, Inc.